 This is an observational, single-cohort, prospective study of systemic chemotherapy after CRSHIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-16 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R R Foundation for Statistical Computing, Vienna, Austria. 